ClinCapture announces AI-powered clinical trial build tech that automates study configuration, and advances intelligent ...

ClinCapture President and CEO Scott Weidley today announced a major expansion of artificial intelligence capabilities within the company's Captivate® platform, embedding AI directly into the ...

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-tar ...

A closer examination of the APOL1 gene in Black patients with kidney disease can provide more accurate diagnoses than current ...

Researchers develop a modified high-resolution magnetic resonance imaging technique for determining the location of ...

The Phase IIa trial is a randomized, placebo-controlled study evaluating the safety, tolerability, and preliminary clinical signals of ONP-002 in patients presenting with acute concussion and mild ...

Introduction Psychedelic-assisted therapy shows promise for treating various mental health conditions; however, its reliance on intensive psychological preparation limits its broader application.

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer ...

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg ...

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance ...

A pilot study has suggested that sustainable approaches to Breast Cancer surgery can be introduced in operating rooms without compromising early clinical outcomes, while also helping reduce the ...

Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.